SBIR Success Rate: Honest Odds by Agency in 2026

The Small Business Innovation Research (SBIR) Phase I success rate runs roughly 10 to 15 percent across most agencies, with real variation by agency and year. Phase II rates are meaningfully higher because only prior Phase I winners may apply. These figures are honest ranges, not promises; agency budgets and application volumes shift every cycle, so treat any single number as an estimate drawn from SBIR.gov, NIH, and NSF data reported through 2026.

Why the odds vary so much between agencies

Success rate is not a measure of how good your science is in the abstract. It is the ratio of awards to applications, and both sides of that ratio differ by agency. An agency with a large appropriation but even larger application volume can post lower odds than a smaller program with fewer applicants. This is why the "easiest" agency changes from year to year and why chasing a rumored high acceptance rate is a poor strategy.

The right move is to target the agency whose mission, topics, and review style fit your technology, then build the most competitive application you can for that audience. Fit beats arithmetic.

How the major agencies compare

Each major participant funds at different volumes and reviews differently:

• National Institutes of Health (NIH): large biomedical portfolio, peer review through study sections on a 1 to 9 impact scale, investigator-initiated topics.
• National Science Foundation (NSF): runs America's Seed Fund, emphasizes technical risk and broad impact, and screens with a required Project Pitch before inviting a full proposal.
• Department of Defense (DoD): narrow, mission-specific topics with a defined customer, often the most prescriptive solicitations.

Because NSF screens with a Project Pitch, its full-proposal pool is partly pre-filtered, which changes how its reported rates compare to agencies that accept all comers. Always read the rate in context of how the agency counts applications.

Why Phase II odds look better

Phase II success rates run higher than Phase I, sometimes substantially, but the comparison is misleading at first glance. Only companies that already won a Phase I can apply for Phase II, so the applicant pool is small and pre-vetted. The higher rate reflects a stronger field, not an easier bar. If you are weighing where to focus, our comparison of Phase I and Phase II goals and funding lays out what each stage demands.

The factors you can actually control

You cannot control your competitors or the agency's budget. You can control whether your proposal is competitive, and that is where preparation pays off.

• Compliance. Noncompliant proposals are rejected before review. Page limits, formatting, and registration codes are non-negotiable.
• Specific Aims. Reviewers often decide on this page. A sharp aims page reframes a borderline application. See how to write Specific Aims that anchor the proposal.
• Feasibility evidence. Even informal preliminary data lifts a proposal out of the speculative pile.
• Commercialization. A credible market path matters even at Phase I and dominates Phase II scoring.
• Resubmission. Many funded companies were rejected first, read their summary statement, and won on the next try.

How a resubmission improves your real odds

The single most underused lever on SBIR odds is the resubmission, because the published Phase I rate counts every first-time and repeat applicant together, while a focused second attempt often performs well above that average. A rejection comes with feedback most applicants never fully use. At NIH, the summary statement records the study section's critiques in detail; at NSF and DoD, a debrief offers the reviewers' reasoning. That feedback is, in effect, a free roadmap for the next submission, written by the exact audience you need to convince.

Treat the first attempt's critique as the outline for the revision. Group the reviewer concerns into themes, address each one explicitly, and where the proposal changed, say so plainly so a returning reviewer sees you listened. The most common winning pattern is not a brand-new idea but a sharpened version of the same one: stronger feasibility evidence answering a "high risk" comment, a tightened Specific Aims page resolving a clarity critique, or a more credible commercialization path responding to a market doubt. Because resubmissions arrive with this advantage, the practical planning move is to budget for two cycles from the start rather than treating a first rejection as the end. Companies that plan for the second attempt convert feedback into funding far more often than those who walk away after one try.

A warning about guaranteed-odds claims

Be skeptical of any consultant, course, or service that quotes a success rate it can deliver for you. No one can guarantee an SBIR award, and reputable professionals will not pretend otherwise. The Grant Professionals Association code of ethics also prohibits charging a percentage of an award, so a contingency offer is both a red flag and an ethics violation. What honest help does is raise the floor of your application's quality. For the full drafting process behind a competitive submission, start with our guide on how to write an SBIR proposal step by step. The same discipline applies across federal funding applications of every kind.

Read the odds as a planning tool, not a verdict

Low success rates are not a reason to skip SBIR; they are a reason to prepare seriously and to budget time for resubmission. Non-dilutive funding that does not cost equity is worth a competitive process. Plan for two attempts, treat the first summary statement as free expert feedback, and target the agency that truly fits your work.